Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.
No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 1990 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
Printed in Switzerland by Thür AG Offsetdruck, Pratteln
ISBN 3-8055-5007-3

Contents

Biology of Schizophrenia
M.S. Keshavan, R. Ganguli (Pittsburgh, Pa.) 1
Introduction 1
Definition of Schizophrenia 2
The Boundary of Schizophrenia 2
Classification of Schizophrenic Subtypes 2
Pathology and Pathophysiology 3
Structural Abnormalities 3
Physiological Dysfunctions 5
Biochemical Changes in Schizophrenia 8
Endocrinology of Schizophrenia 12
Neuropsychological Dysfunction 13
'Soft'Neurological Signs in Schizophrenia 14
Etiological Factors in Schizophrenia 14
Genetic Factors in Schizophrenia 14
Perinatal Influences 16
Autoimmune Hypothesis 16
Viral Hypothesis 20
Summary and Conclusions 23
References 24

Treatment of Schizophrenia
J.M. Davis, J.R. Barter (Chicago, 111.) 34
Development of the Controlled Clinical Trial 34
Efficacy 35
Time Course 36
Do Antipsychotics Alter the Natural Course of Schizophrenia? 36
Comparative Efficacy and Spectrum of Different Antipsychotics 38
Indications 40
Relationship of Dose to Clinical Response 41

Contents VI

Psychological Effects of Antipsychotics 45
Long-Term Maintenance Effects of Antipsychotics 46
Time Course of Relapse of Schizophrenia 48
Indications for Maintenance Treatment 50
Targeted Treatment 51
Depot Long-Acting Antipsychotics 52
Mechanism of Action 53
Combined Antipsychotic with Other Treatment 55
Physical Treatment 55
Psychosocial and Drug Treatment for Psychosis 56
Inpatient Studies 56
Outpatient Studies 58
References 61

Serotonin in Psychiatric Pathophysiology
A Review of Data from Experimental and Clinical Research
E. Eriksson (Göteborg), M. Humble (Dandryd) 66
Anatomy and Function of Brain Serotonergic Neurons 66
Serotonin Receptors 68
Introduction 68
5-HTia Receptors 69
5-HTib Receptors 70
5-HTic Receptors 71
5-HTid Receptors 71
5-HT2 Receptors 71
5-HT3 Receptors 72
5-HT Receptors: Concluding Remarks 72
Effects of Different Psychoactive Treatments on Serotonin Neurotransmission . . 73
Hypothalamic and Hormonal Mechanisms 184
Neurotransmitter Systems 185
Norepinephrine 186
Adrenergic Receptor Effects 186
Serotonin 187
Dopamine 188
Acetylcholine 189
Endogenous Opioids 189
Gamma Aminobutyric Acid 190
Adenosine 192
Neurophysiology 192
Anticonvulsant Properties 192
Cognitive Effects 193
Mechanisms Underlying Electroconvulsive Therapy-Induced Cognitive Impairment 195
Neuropathology 196
Summary and Conclusions 197
Efficacy and Side Effects 197
Mechanisms 198
References 199

The Mood-Stabilizing Drugs
A.K. Jain (Kansas City, Mo.), S. Kelwala (Northville, Mich.),
D. Willsie (Kansas City, Mo.) 211
Lithium 213
Anticonvulsants as Mood-Stabilizing Agents 215
Valproic Acid 219
Clonazepam 221
Verapamil-Calcium Channel Blockers 223

Contents IX

Serotonergic Agents: Tryptophan . 225
Adrenergic Agents in Mania: Clonidine 228
Propranolol in Mania 229
Cholinergic Agents in Mania 231
Dopaminergic Agents in Manic-Depressive Illness 231
Conclusion 233
References 234

Neurobiological Mechanisms of Human Anxiety
D.S. Charney, S.W. Woods, J.H. Krystal (New Haven, Conn.),
G.R. Heninger (West Haven, Conn.) 242
Neuroanatomical Substrates for Anxiety or Fear 242
The Role of Noradrenergic Function in Human Anxiety 244
Clinical Investigations of Noradrenergic Function in Anxiety Disorders 249
A Noradrenergic Neurodevelopmental Theory of Panic Disorder 251
Noradrenergic Function and the Mechanism of Action of Antipanic Treatment 253
The Role of Serotonin Function in Human Anxiety 254
Preclinical Investigations 255
Neuroanatomical Substrates for Anxiety of Fear and Their Relation to the Serotonin Hypothesis of Anxiety 256
Laboratory Animal Behavioral Models of Anxiety and Fear: Relationship to Serotonin Function 257
Clinical Investigations of Serotonin Function in Anxiety Disorders 258
Efficacy and Mechanism of Serotonin Specific Drugs in Anxiety Disorders 259
Current Status of the Serotonin Hypotheses of Human Anxiety 260
The Role of the Benzodiazepine-GABA System in Anxiety 261
Preclinical Investigations 261
Clinical Investigations 262
The Benzodiazepine Receptor and the Mechanism of Anxiolytic Action of Benzodiazepines 264
Implications of Benzodiazepine Anxiolytic Efficacy for the Pathophysiology of Anxiety Disorders 265
Adenosine Function and Panic Anxiety 266
The Role of Dopamine Neuronal Activity in Anxiety 267
The Role of Corticotrophin-Releasing Hormone in Anxiety 267
Lactate Induction of Panic Attacks 268
Brain Imaging during Panic Attacks 268
Concluding Remarks 268
References 270

Biological Treatment of Anxiety Disorders
R. Balon, R. Pohl, V.K. Yeragani (Detroit, Mich.) 284
Panic Disorder 285
Tricyclic Antidepressants 285
Second Generation Antidepressants 287

Contents X

Monoamine Oxidase Inhibitors 288
Benzodiazepines 289

-Blocking Agents 291
Azaspirodecanediones 292
Miscellaneous Drugs 292
Generalized Anxiety Disorder 293
Benzodiazepines 294
Tricyclic Antidepressants 295

Beta-Blocking Agents 296
Azaspirodecanediones 297
Performance Anxiety 298
Social Phobia 299
Obsessive-Compulsive Disorder 300
Post-Traumatic Stress Disorder 301
Conclusion 302
References 303

Subject Index 311